Clinical trial · no report yet · Phase 3
NCT05244798
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
- NCT05244798 ↗
- Not yet recruiting
- Sichuan Cancer Hospital and Research Institute
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy Plus Sintilimab Versus Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Controlled, Phase III Trial
- Phase
- Phase 3
- Status
- Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Sintilimab; radiotherapy; Chemotherapy
- Arms
- Group of sintilimab combined with neoadjuvant chemotherapy · Experimental
- Group of sintilimab combined with neoadjuvant chemoradiotherapy · Experimental
- Group of neoadjuvant chemoradiotherapy · Other
- Enrollment
- 420 (estimated)
- Primary outcomes
- Pathology complete response rate, pCR
- Sponsor
- Sichuan Cancer Hospital and Research Institute with Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Hebei Medical University Fourth Hospital, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, Anyang Tumor Hospital, Shantou Central Hospital, Innovent Biologics (Suzhou) Co. Ltd., GeneCast Biotechnology Co., Ltd.
- Start
- Nov 1, 2022 (estimated)
- Primary completion
- Dec 31, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05244798 · updated Oct 25, 2022
Publications
linked from the registry- He W, Bai H, Lv J, Tang P, Hu T, Zhou H, Xiao W, Peng L, Liu G, Wang K, Fang Q, Qi Y, Liang L, Zheng X, Qing H, Chen Y, Zhou Y, Xie W, Han Y, Leng X. Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study). BMJ Open. 2025 Jun 4;15(6):e095828. doi: 10.1136/bmjopen-2024-095828. PubMed 40467307